Learn about our expanded patient care options and visitor guidelines.
General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts
Enter the last name, specialty or keyword for your search below.
Dr. Sperati’s group focuses on complement mediated kidney disorders, glomerular disease, and renal arterial disease secondary to fibromuscular dysplasia. His team has a particular interest in thrombotic microangiopathies involving the complement system.
Dr. Parikh's research focuses on the translation and validation of novel biomarkers for the diagnosis and prognosis of acute kidney injury. Progress in kidney diseases has been hamstrung by significant heterogeneity within the current disease definitions, which are largely based on serum creatinine. Dr. Parikh's research has addressed this critical challenge by developing biomarkers of renal tubular injury, repair, and inflammation to dissect this heterogeneity. He has assembled multicenter longitudinal prospective cohorts for translational research studies across several clinical settings of acute kidney injury and chronic kidney disease for the efficient translation of novel biomarkers.
His research is dedicated to the process of applying discoveries generated in the laboratory and in preclinical experiments, the development of clinical studies, and the design of clinical trials. Dr. Parikh's studies have refined the clinical definition in perioperative acute kidney in...jury and hepatorenal syndrome, developed strategies to reduce kidney discard in deceased donor transplantation, and advanced regulatory approvals of kidney injury biomarkers. He has also developed biomarkers to identify rapid progressors of early diabetic kidney disease before derangements in serum creatinine. Dr. Parikh's research goal is to translate our understanding of pathophysiological mechanisms into clinical practice and improve the outcomes in patients with kidney disease.
Dr. Parikh has also been the recipient of numerous honors, including the 2017 Young Investigator Award from the American Society of Nephrology.
view more
Dr. Geetha’s team focuses on renal diseases in patients with systemic vasculitis as well as BK virus nephropathy in patients who have undergone renal transplant. Our studies include clinical trials on the effectiveness of rituximab versus cyclosporine in treating idiopathic membranous nephropathy and a multinational study of belimumab with azathioprine for maintaining remission of granulomatosis with polyangiitis and microscopic polyangiitis. We also have conducted research on the treatment of ANCA vasculitis, particularly in kidney transplant patients.
Research in the Edgar Miller Lab focuses on nutrition, hypertension and kidney disease. Current projects include a National Heart, Lung, and Blood Institute study on dietary carbohydrate and glycemic index effects on markers of oxidative stress, inflammation and kidney function; and a National Institute of Diabetes and Digestive and Kidney Diseases randomized controlled trial that examines the effects of omega-3 fatty acid supplementation on urine protein excretion in diabetic kidney disease.
The Elizabeth Selvin Lab examines the intersection of epidemiology, clinical policy and public health policy. One of our key goals is to use the findings of epidemiologic research to inform the screening, diagnosis and treatment of diabetes, cardiovascular disease and kidney disease. Much of our work looks at biomarkers and diagnostics related to diabetes and diabetes complications. Our findings — linking hemoglobin A1c (HbA1c) to diabetic complications and identifying the role of A1c in diabetes diagnosis — have influenced clinical practice guidelines.
Dr. Rabb’s lab is involved in translational research aimed at understanding the molecular pathogenesis of kidney ischemia/reperfusion injury. The lab is interested in the development of novel treatments for kidney IRI.
Research in the J. Hunter Young Lab focuses on the genetic epidemiology and physiology of cardiovascular disease and its risk factors, especially hypertension, diabetes and obesity. Current activities include an observational study of hypertension among African Americans; a genetic epidemiology study of worldwide cardiovascular disease susceptibility patterns; and several population-based observational studies of cardiovascular and renal disease. A recent focus group study found that changes in housing and city policies might lead to improved environmental health conditions for public housing residents.
Research in the Josef Coresh Lab focuses on cardiovascular epidemiology, kidney disease and genetic epidemiology. Our team uses innovative methods to quantify disease burden and consequences in the population; studies the causes and consequences of vascular disease in the heart, kidneys and brain; and works to develop a strong scientific basis for quantifying the burden, causes and consequences of kidney disease. Working in collaboration with leading laboratories and specialists, we also aim to quantify the interplay of genes and environment in health and disease.
Research in the Liudmila Cebotaru Lab studies cystic fibrosis transmembrane conductance regulator (CFTR) mutants. We also investigate corrector molecules that are currently in clinical trials to get a better understanding of their mechanism of action. A major focus of our research is on developing more efficient gene therapy vectors with the ultimate goal of developing a gene therapy for cystic fibrosis.
Research in the Mark Sulkowski Lab focuses on hepatitis B and hepatitis C. We've conducted clinical research related to the management of viral hepatitis, including novel agents. Other studies focus on adult patients at the Johns Hopkins site of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Hepatitis B Clinical Research Network as well as the National Institute of Allergy and Infectious Diseases Adult AIDS Clinical Trials Group.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
